Buy Mavixen 100 MG _ 40 MG (Glecaprevir _ Pibrentasvir ) - Mediaid pharmacy

Mavixen 100 MG / 40 MG (Glecaprevir / Pibrentasvir )

Product Name : Mavixen
Generic Name : Glecaprevir 100 mg/Pibrentasvir 40 mg
Formulation : Tablet
Available Pack Size : 30’s Pot
Available Strengths : 40mg & 100mg
Registrations : Export Only

Message Us on WhatsApp

Product Information

Mavixen (Glecaprevir 100mg / Pibrentasvir 40mg) is a fixed-dose, pangenotypic combination of two direct-acting antivirals used to treat chronic Hepatitis C Virus (HCV) infection across genotypes 1 through 6. It works by combining an NS3/4A protease inhibitor (Glecaprevir) with an NS5A inhibitor (Pibrentasvir), blocking two distinct stages of the HCV replication cycle to achieve high cure rates in short treatment courses. Manufactured by Everest Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.

Basic Product Information of Mavixen (Glecaprevir/Pibrentasvir)

Brand Name	Mavixen (Glecaprevir/Pibrentasvir)
Generic Name	Glecaprevir 100mg / Pibrentasvir 40mg (Fixed-Dose Combination, per tablet)
Drug Class	HCV NS3/4A Protease Inhibitor + HCV NS5A Inhibitor (Direct-Acting Antiviral Combination)
Strength per Tablet	Glecaprevir 100mg and Pibrentasvir 40mg (fixed-dose combination in a single tablet)
Formulation	Film-Coated Tablet
Pack Size	30 Tablets per Pot
Primary Indication	Chronic Hepatitis C Virus (HCV) Infection, Genotypes 1 to 6
Regulatory Approvals	USFDA Approved (Pangenotypic HCV, Ages 3 and Above). EMA Approved. Carries an FDA Boxed Warning for HBV reactivation risk.
Originator Brand	Mavyret by AbbVie
Manufacturer	Everest Pharmaceuticals Ltd., Dhaka, Bangladesh
Global Supplier	Mediaid Pharmacy, Worldwide Shipping Available
Registration Status	Export Only – Manufactured for International Markets
Storage Conditions	Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children.

How Mavixen (Glecaprevir/Pibrentasvir) Works

Each Mavixen tablet combines two direct-acting antivirals that target different steps of the Hepatitis C virus (HCV) life cycle. Glecaprevir is an inhibitor of the HCV NS3/4A protease, an enzyme the virus needs to process its polyprotein into functional viral proteins. Pibrentasvir is an inhibitor of NS5A, a protein essential for HCV RNA replication and the assembly of new virus particles.

By blocking these two distinct, essential steps simultaneously, Mavixen suppresses HCV replication effectively across all six major genotypes of the virus, making it a pangenotypic treatment option. This dual mechanism, combined with a high genetic barrier to resistance, allows most patients to achieve a sustained virologic response (effectively, a cure) with a relatively short treatment course.

Mavixen is taken as a once-daily oral tablet combination, with food, and the duration of treatment is individualised based on HCV genotype, prior treatment history, and the presence or absence of cirrhosis, as determined by the prescribing physician.

Indications for Mavixen (Glecaprevir/Pibrentasvir)

Mavixen (Glecaprevir/Pibrentasvir) is indicated for the following conditions:

Chronic HCV Without Cirrhosis or With Compensated Cirrhosis

For patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection who have no cirrhosis or have compensated cirrhosis (Child-Pugh A).

Genotype 1, Previously Treated Patients

For patients with HCV genotype 1 infection previously treated with a regimen containing either an NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

Liver or Kidney Transplant Recipients

For patients who are liver or kidney transplant recipients with chronic HCV infection, and for patients with HCV/HIV-1 co-infection, following genotype- and treatment-history-specific dosing guidance.

Benefits of Mavixen (Glecaprevir/Pibrentasvir)

Pangenotypic Coverage

Mavixen is effective across all six major HCV genotypes, removing the need for genotype testing to select the right regimen in many treatment scenarios.

Short Treatment Duration

Many treatment-naive patients without cirrhosis can achieve a cure in as little as 8 weeks, one of the shortest standard treatment courses available for chronic HCV.

High Cure Rates

Clinical trials of Glecaprevir/Pibrentasvir have demonstrated very high sustained virologic response rates across genotypes and patient populations, including those with compensated cirrhosis.

Affordable Alternative to Mavyret

Mavixen contains the same active ingredients as Mavyret by AbbVie, at a significantly lower cost, making curative HCV therapy more financially accessible to patients worldwide.

Convenient Once-Daily Regimen

All three daily tablets are taken together, once a day, with food, offering a simple regimen without injections or complex dosing schedules.

cGMP Certified Manufacturing

Produced by Everest Pharmaceuticals Ltd. under cGMP-compliant manufacturing standards, helping ensure consistent quality, purity, and potency in every batch of Mavixen tablets.

How to Take Mavixen (Glecaprevir/Pibrentasvir)

Route: Oral, taken with food. Tablets should be swallowed whole and not chewed, crushed, or split.

Standard dose: Three tablets taken together, at the same time, once daily with food (total daily dose: Glecaprevir 300mg and Pibrentasvir 120mg).

Treatment duration: Typically 8 weeks for treatment-naive patients without cirrhosis; 12 weeks for patients with compensated cirrhosis or certain treatment-experienced patients; and up to 16 weeks in specific genotype and treatment-history scenarios. Duration is individualised by the prescribing physician based on genotype, cirrhosis status, and prior treatment history.

Missed dose: If a dose is missed and remembered within 18 hours of the usual time, take it as soon as possible; if more than 18 hours have passed, skip the missed dose and resume the normal schedule the next day.

Hepatic impairment: No dose adjustment is required for mild hepatic impairment (Child-Pugh A). Mavixen is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) or any history of prior hepatic decompensation.

Renal impairment: No dose adjustment is required based on renal function, including patients with severe renal impairment or on dialysis.

Contraindicated combinations: Mavixen must not be co-administered with atazanavir or rifampin.

Paediatric use: Approved for paediatric patients 3 years of age and older, with weight-based dosing guidance for younger or smaller patients, as directed by a specialist.

Boxed Warning – Prescription Medication. Mavixen carries a boxed warning for the risk of Hepatitis B Virus (HBV) reactivation in patients co-infected with HCV and HBV, which has led to fulminant hepatitis, liver failure, and death in some cases. All patients must be tested for current or prior HBV infection before starting Mavixen, and HBV-coinfected patients require monitoring during and after treatment. Mavixen must only be prescribed and monitored by a physician experienced in managing HCV therapy.

Monitoring and Dosage Adjustments

Before starting Mavixen, all patients must be tested for current or prior Hepatitis B virus infection. Your physician will also assess baseline liver function and screen for any history of hepatic decompensation. During treatment, monitoring may include periodic liver function tests, particularly if symptoms suggestive of liver injury develop, and, where relevant, INR or blood glucose monitoring in patients taking warfarin or diabetes medications, since Mavixen can affect the levels of certain concomitant drugs. Report any yellowing of the skin or eyes, dark urine, unusual fatigue, or abdominal pain to your doctor immediately.

Drug Interactions and Important Information

Mavixen must never be combined with atazanavir or rifampin, as these are contraindicated combinations. Use caution with certain statins (such as atorvastatin, rosuvastatin, simvastatin, and lovastatin), as Mavixen can significantly increase their plasma concentrations; dose adjustment or temporary discontinuation of the statin may be required. Caution is also needed with digoxin and other P-glycoprotein substrate medications, and with strong inhibitors of OATP1B1/3 transporters.

Combined hormonal contraceptives containing ethinyl estradiol should be avoided during treatment, due to the risk of elevated liver enzymes. Patients on warfarin should have their INR monitored closely, and patients with diabetes should have blood glucose monitored, as glycaemic control may improve during and after successful HCV treatment. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Mavixen.

Side Effects and Precautions

Common Side Effects

Headache

Fatigue

Nausea

Diarrhoea

Mild, transient elevations in bilirubin

Serious Warnings and Precautions

Hepatitis B virus reactivation in HCV/HBV coinfected patients, potentially fatal. Requires baseline HBV testing.

Hepatic decompensation and hepatic failure, primarily reported in patients with pre-existing advanced or decompensated cirrhosis, in whom the drug is contraindicated.

Risk of significant drug interactions with certain statins, hormonal contraceptives, and other concomitant medications.

Who Should Use Mavixen (Glecaprevir/Pibrentasvir)?

Mavixen is suitable for adult and paediatric patients aged 3 years and older with chronic Hepatitis C virus infection across genotypes 1 through 6, including those with compensated cirrhosis, prior treatment experience with certain HCV regimens, or HCV/HIV-1 co-infection. It is prescribed by hepatologists, gastroenterologists, and infectious disease specialists experienced in managing chronic HCV. A thorough medical assessment including HCV genotype testing where relevant, HBV testing, and baseline liver function is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Mavixen under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Mavixen is one of Everest’s specialty virology products, offering a bioequivalent alternative to Mavyret by AbbVie at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty medications. We ensure Mavixen (Glecaprevir/Pibrentasvir) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Mavixen (Glecaprevir/Pibrentasvir) from Mediaid Pharmacy?

Mavixen represents one of the most effective and convenient options in modern Hepatitis C treatment. As the generic equivalent of Mavyret by AbbVie, it delivers the same active ingredients, Glecaprevir and Pibrentasvir, with the same proven pangenotypic mechanism and short treatment durations at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Mavixen gives patients worldwide access to curative HCV therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Glecaprevir/Pibrentasvir option with worldwide delivery, Mavixen from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Mavixen (Glecaprevir/Pibrentasvir)

What is Mavixen used for?

Mavixen (Glecaprevir/Pibrentasvir) is used to treat chronic Hepatitis C virus infection across genotypes 1 through 6 in adults and children aged 3 years and older, including patients with compensated cirrhosis, certain treatment-experienced patients, and transplant recipients. It works by blocking two essential steps in the HCV replication process.

How should I take Mavixen?

Three Mavixen tablets are taken together, once daily, with food. Treatment duration is typically 8 to 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment history, as determined by your physician. It is important to complete the full prescribed course even if you feel well.

What strength is Mavixen available in?

Each Mavixen tablet is a fixed-dose combination containing 100mg of Glecaprevir and 40mg of Pibrentasvir, supplied in a pot of 30 tablets. Since three tablets are taken together each day, one pot provides a 10-day supply; your physician will advise on the total number of pots needed for your full treatment course.

Is Mavixen the same as Mavyret (Glecaprevir/Pibrentasvir by AbbVie)?

Yes. Mavixen is the generic equivalent of Mavyret. Both contain the same active ingredients, Glecaprevir and Pibrentasvir, in the identical fixed-dose combination. Mavixen is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and delivers the same clinical mechanism as Mavyret at a significantly lower cost.

What are the side effects of Mavixen?

Common side effects include headache, fatigue, nausea, and diarrhoea. The most important risk is Hepatitis B virus reactivation in patients also infected with HBV, which is why all patients are tested for HBV before starting treatment. Always consult your physician for a complete assessment of your individual risks and benefits before starting treatment.

Can Mavixen be used with other medications?

Mavixen must never be combined with atazanavir or rifampin. Caution is needed with certain statins, digoxin, warfarin, and hormonal contraceptives containing ethinyl estradiol. Always inform your physician of all medications, supplements, and herbal products you are taking before starting Mavixen.

Is Mavixen safe during pregnancy or breastfeeding?

Data on Mavixen use during pregnancy and breastfeeding are limited. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding, so that the potential risks and benefits can be discussed in the context of your individual situation.

Can I order Mavixen online with worldwide shipping?

Yes. Mediaid Pharmacy supplies Mavixen (Glecaprevir/Pibrentasvir) globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.

Order Mavixen (Glecaprevir 100mg / Pibrentasvir 40mg) with Worldwide Shipping

Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com

Message on WhatsApp